EYE1090 是一种具有口服活性的 VEGFR2 抑制剂(IC50 为 3 nM),可抑制血管生成、内皮细胞迁移及 VEGFR2 诱导的视网膜渗漏,并能减小小鼠脉络膜新生血管病灶的大小,可用于年龄相关性黄斑变性、糖尿病视网膜病变和脉络膜新生血管的相关研究。
产品编号: MS-B16790 CAS No.: 3037217-70-9 分子式: C22H26ClN7O2 分子量: 455.94
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

EYE1090 是一种具有口服活性的 VEGFR2 抑制剂(IC50 为 3 nM),可抑制血管生成、内皮细胞迁移及 VEGFR2 诱导的视网膜渗漏,并能减小小鼠脉络膜新生血管病灶的大小,可用于年龄相关性黄斑变性、糖尿病视网膜病变和脉络膜新生血管的相关研究。

生物实验数据

生物活性 EYE1090 is an orally active VEGFR2 inhibitor with an IC50 of 3 nM that inhibits angiogenesis, endothelial cell migration, and VEGFR2-induced retinal leakage, reduces the size of choroidal neovascularization lesions in mice, and can be used for research on age-related macular degeneration, diabetic retinopathy, and choroidal neovascularization.
IC50 & Target

VEGFR-2

 

体外研究
(In Vitro)

EYE1090 在黑暗条件下可抑制纯化的 VEGFR2 激酶,其 IC50 为 13 nM;光照可增强其效力,使 IC50 降至 3 nM。
EYE1090 (0.1-100 μM; 24 h) 可呈剂量依赖性降低 NIH/3T3 成纤维细胞的活力。
EYE1090 (50 min pre-incubation; 10 min light exposure; 4 h VEGF stimulation) 可在冷白光 LED 条件下的黑暗环境中以 19.06 nM 的 IC50、红光 LED 条件下以 21.75 nM 的 IC50、绿光 LED 条件下以 33.37 nM 的 IC50 抑制 VEGFR2/NFAT 报告基因 HEK293 细胞中 VEGF 诱导的 VEGFR2 信号通路;冷白光或绿光 LED 照射可显著增强其效力,而红光 LED 无此作用。
EYE1090 (1-100 nM; 1 h pre-incubation; 10 min light exposure; 10 min VEGF stimulation) 在黑暗条件下不会显著抑制 VEGFR2/NFAT 报告基因 HEK293 细胞中 VEGF 诱导的 VEGFR2 在 Y951 或 Y1175 位点的磷酸化,但光照会触发对这些位点磷酸化的强效抑制作用。
EYE1090 (0.1 nM-10 μM; 10 min pre-incubation; 10 min light exposure; 12 h incubation) 在黑暗条件下可抑制 HRMEC 的管形成,IC50 为 410 nM;而光照可增强其效力,使 IC50 降至 133 nM,消除了其与舒尼替尼之间的效力差距。
EYE1090 (0.001-10 μM; 10 min pre-incubation; 10 min light exposure; 6 h migration incubation) 可在黑暗条件下抑制 HRMEC 的迁移,其 IC50 为 1012 nM;而光照可增强其效力,使 IC50 降至 474 nM。

Cell Viability Assay

Cell Line: NIH/3T3 fibroblasts
Concentration: 0.1; 1; 10; 50; 75; 100 μM
Incubation Time: 24 h
Result: Reduced NIH/3T3 cell viability in a dose-dependent manner.
Was significantly less toxic than its parental compound sunitinib at concentrations above 75 μM (p<0.05).

Western Blot Analysis

Cell Line: VEGFR2/NFAT Reporter-HEK293 recombinant cell line
Concentration: 1; 10; 50; 100 nM
Incubation Time: 1 h pre-incubation; 10 min light exposure; 10 min VEGF stimulation
Result: Did not substantially inhibit VEGF-induced phosphorylation of VEGFR2 at Y951 or Y1175 in the dark, even at 100 nM.
Significantly suppressed VEGF-induced phosphorylation of VEGFR2 at Y951 or Y1175 with light exposure.
Left total VEGFR2 and β-actin levels unchanged, confirming no receptor degradation or loading differences.
体内研究
(In Vivo)

EYE1090 (40 mg/kg;灌胃;单次给药) 在小鼠中会因光照显著降低其全身血清浓度。
EYE1090 (1 mg/kg;灌胃;每日一次;连续 3 天) 可显著减少 Long Evans 大鼠中由 VEGF 诱导的视网膜血管渗漏。
EYE1090 (1 mg/kg;灌胃;每日;连续 3 天) 可显著减小小鼠的脉络膜新生血管 (CNV) 病灶面积。
EYE1090 (40 mg/kg;灌胃;单次给药) 在正常或暗红色光条件下不会对小鼠产生肝毒性。

Animal Model: BALB/cJRj mice (male, 8 weeks old)
Dosage: 40 mg/kg
Administration: i.g.; single dose
Result: Reduced mean serum concentrations by more than 50% in white light-exposed group compared to dark-treated controls.
Increased significantly in the dark condition.
Showed no significant increase in the light-exposed group.
Animal Model: Long Evans rats (male, 200-250 g) intravitreally injected with VEGF (50 ng/eye) on day3
Dosage: 1 mg/kg
Administration: i.g.; daily; 3 days
Result: Reduced VEGF-induced retinal vascular permeability significantly, with permeability values in VEGF-injected eyes significantly lower than those in VEGF-only control eyes.
Showed permeability values not significantly different from control eyes without VEGF injection.
Animal Model: Adlut C57BL/6JRj mice (9 weeks old) with choroidal neovascularization (CNV)
Dosage: 1 mg/kg
Administration: i.g.; daily; 3 days
Result: Reduced CNV lesion area highly significantly compared to vehicle controls by day 5.
Decreased lesion area through day 7, remaining significantly lower than vehicle controls.
Animal Model: BALB/cJRj (male and female, 6-10 weeks old)
Dosage: 40 mg/kg
Administration: i.g.; single dose
Result: Showed intact liver architecture, normal glycogen storage, and no evidence of necrosis, cellular stress, fibrosis, or abnormal collagen deposition under either normal light/dark cycles or continuous dim red light conditions.

化学信息

分子量 455.94
分子式 C22H26ClN7O2
CAS No. 3037217-70-9

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础